Dopamine in Lesch-Nyhan Disease

Awardee: Jasper Visser

Institution: Radboud University Medical Center, Nijmegen, The Netherlands

Grant Amount: $85,779.00

Funding Period: February 1, 2023 - January 31, 2024


Summary:

In Lesch-Nyhan disease (LND), it is unknown why the loss of a very generic protein that is present in all cells of the body causes such a specific brain dysfunction with abnormal movements and self-injury. It is thought that brain cells that use the neurotransmitter dopamine to pass on signals to other brain cells are particularly affected in LND, but it is not known whether these are the only brain cells that are affected. This project investigates in a mouse model for LND whether repairing these dopamine neurons alone would be sufficient to prevent or treat the brain abnormalities in LND. If that is the case, they could serve as the primary target for future therapies.

Publications:

Very Early Levodopa May Prevent Self-Injury in Lesch-Nyhan Disease

Previous
Previous

Assessing and quantifying gait problems in patients with STXBP1-related disorders using three-dimensional gait analysis

Next
Next

PET Radiotracer development based on existing ATM-inhibitors